NMSC Immunotherapy Guide IAR App Icon

NMSC Immunotherapy Guide IAR

Medical • Med Learning Group
17+ v1.0 Recorded price: Free App Store →
IPA Analysis
Technical Specs
Bundle ID com.mlg.nmsciar
Version 1.0
App Store Size 465.38 MB
Minimum iOS 13.0
Devices iPhone, iPad, iPod touch
Catalog release date 2026-05-28
Latest recorded version date 2026-05-28
Features & Support
Advisory 17+
Frequent/Intense Medical/Treatment Information
Languages (1)
EN
Top In App Purchases
No In App Purchases Listed

Preview

NMSC Immunotherapy Guide IAR screenshot 1 NMSC Immunotherapy Guide IAR screenshot 2 NMSC Immunotherapy Guide IAR screenshot 3 NMSC Immunotherapy Guide IAR screenshot 4 NMSC Immunotherapy Guide IAR screenshot 5 NMSC Immunotherapy Guide IAR screenshot 6

Description

In nonmelanoma skin cancer (NMSC), particularly cutaneous squamous cell carcinoma (cSCC), treatment selection has evolved with the integration of immune checkpoint inhibitors (ICIs) across multiple stages of disease. Current guidelines support a risk-adapted approach in which ICIs play a central role for patients with high-risk, locally advanced, or metastatic disease, as well as an emerging role in earlier treatment settings. For unresectable or metastatic disease, ICIs targeting the PD-1/PD-L1 pathway are the preferred systemic therapy, offering durable responses and a favorable tolerability profile compared with traditional approaches. Their use is supported by the underlying tumor biology of cSCC, which is characterized by a high tumor mutational burden driven by ultraviolet radiation exposure. This leads to increased neoantigen formation and enhanced tumor immunogenicity, making these tumors particularly responsive to immune modulation. In addition, upregulation of immune checkpoint pathways such as PD-1/PD-L1 contributes to immune evasion, providing a strong mechanistic rationale for checkpoint blockade. Beyond advanced disease, ICIs are increasingly being incorporated into neoadjuvant and adjuvant treatment strategies for high-risk, resectable NMSC. In the neoadjuvant setting, ICIs may reduce tumor burden, improve surgical outcomes, and, in some cases, enable less extensive resections. In the adjuvant setting, they are being explored to reduce the risk of recurrence following surgery, particularly in patients with high-risk pathologic features. These approaches reflect a shift toward earlier immune intervention in the disease course.

Technical Analysis

Package Overview Basic metadata
Bundle ID com.mlg.nmsciar
Current Version 1.0
Minimum iOS 13.0
Package Size App Store Size
Package Metadata 0 / 1 version records
Detailed binary, privacy manifest, framework, and Info.plist results have not been indexed for this package yet. The verified App Store and archive metadata above remains available.

Developer Information

Known Version Records

0 version records with stored package metadata • 1 known version records

Stored metadata does not guarantee a package is currently available to download.

Archived versions of NMSC Immunotherapy Guide IAR
Details Version / IDs Version date Action
NMSC Immunotherapy Guide IAR icon
Not archived
App Store ID: 885920438 Unknown Request Version